{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:36:31Z","timestamp":1774438591557,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024216","name":"College of Health Sciences, University of KwaZulu-Natal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024216","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"publisher","award":["CSA2020NoE-3102-EACCR3"],"award-info":[{"award-number":["CSA2020NoE-3102-EACCR3"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007941","name":"Addis Ababa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jctube.2025.100515","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:36:52Z","timestamp":1741174612000},"page":"100515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia"],"prefix":"10.1016","volume":"39","author":[{"given":"Bisrat","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimtubezinash","family":"Woldeamanuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigest","family":"Ajeme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mbazi","family":"Senkoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsegahun","family":"Manyazewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2025.100515_b0005","unstructured":"Tuberculosis2024."},{"key":"10.1016\/j.jctube.2025.100515_b0010","unstructured":"Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jctube.2025.100515_b0015","unstructured":"Tuberculosis in the WHO African Region: 2023 progress update. Brazzaville: WHO African Region, 2023. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jctube.2025.100515_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jctube.2024.100481","article-title":"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: a retrospective cohort study","volume":"37","author":"Khan","year":"2024","journal-title":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"},{"issue":"4s","key":"10.1016\/j.jctube.2025.100515_b0025","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.ijtb.2020.09.027","article-title":"Adverse drug reactions & drug interactions in MDR-TB patients","volume":"67","author":"Gupta","year":"2020","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.jctube.2025.100515_b0030","unstructured":"Briefing Note Safety of medicines -adverse drug reactions Key facts WHO."},{"issue":"4","key":"10.1016\/j.jctube.2025.100515_b0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","article-title":"Adverse drug reactions in tuberculosis and management","volume":"66","author":"Prasad","year":"2019","journal-title":"Indian J Tuberc"},{"issue":"5","key":"10.1016\/j.jctube.2025.100515_b0040","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1097\/MJT.0000000000000421","article-title":"Occurrence, management, and risk factors for adverse drug reactions in multidrug resistant tuberculosis patients","volume":"25","author":"Ahmad","year":"2018","journal-title":"Am J Ther"},{"issue":"3","key":"10.1016\/j.jctube.2025.100515_b0045","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4269\/ajtmh.19-0175","article-title":"Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in angola","volume":"101","author":"Aznar","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.jctube.2025.100515_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255357","article-title":"Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam","volume":"16","author":"Ngoc","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100515_b0055","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/TCRM.S423163","article-title":"Magnitude and impacts of adverse events of injectable containing shorter regimen in programmatic management of multi-drug resistant tuberculosis in ethiopia: a retrospective cohort study","volume":"19","author":"Achalu","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jctube.2025.100515_b0060","doi-asserted-by":"crossref","unstructured":"El-Din MAT HH, El-Tantawy AM. Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009. Egyptian Journal of Chest Diseases and Tuberculosis 2015 Jul;64(3):657\u201364. 38. 2015.","DOI":"10.1016\/j.ejcdt.2015.05.011"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12879-023-08085-3","article-title":"Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda","volume":"23","author":"Ategyeka","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jctube.2025.100515_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212948","article-title":"Putting in harm to cure: drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. experience from a tertiary hospital in Italy","volume":"14","author":"Gualano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100515_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/412893","article-title":"Adverse reactions to antituberculosis drugs in iranian tuberculosis patients","volume":"2014","author":"Farazi","year":"2014","journal-title":"Tuberculosis Research and Treatment"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12879-019-3919-1","article-title":"Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study","volume":"19","author":"Merid","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jctube.2025.100515_b0085","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2147\/IDR.S351076","article-title":"A score to predict the risk of major adverse drug reactions among multi-drug resistant tuberculosis patients in Southern Ethiopia, 2014-2019","volume":"15","author":"Bogale","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jctube.2025.100515_b0090","unstructured":"Guidelines for Clinical and Programmatic Management of TB, TB\/HIV, DR-TB and Leprosy in Ethiopia . 7th ed. 2021. Ethiopia2021 2021."},{"issue":"2","key":"10.1016\/j.jctube.2025.100515_b0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5588\/pha.20.0065","article-title":"Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019","volume":"11","author":"Tesema","year":"2021","journal-title":"Public Health Action"},{"key":"10.1016\/j.jctube.2025.100515_b0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4236\/jtr.2014.23018","article-title":"Prevalence and risk factors of adverse drug reactions associated multidrug resistant tuberculosis treatments in selected treatment centers in Addis Ababa Ethiopia","volume":"2014","author":"Bezu","year":"2014","journal-title":"Journal of Tuberculosis Research"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijmyco.2015.10.002","article-title":"Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study","volume":"5","author":"Wondwossen","year":"2016","journal-title":"Int J Mycobacteriol"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40360-019-0313-y","article-title":"Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study","volume":"20","author":"Shibeshi","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jctube.2025.100515_b0115","unstructured":"Aradimitriou N., Cheru F., Wondimu A., Yacobi H., Eyob AE., Belay F., Temesgen T. K., Eyana SM., Yoseph S. (2021) \u2018The State of Addis Ababa 2021: Towards A Healthier City\u2019. Addis Ababa: UN Habitat."},{"key":"10.1016\/j.jctube.2025.100515_b0120","unstructured":"Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jctube.2025.100515_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.883483","article-title":"Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: analysis from a prospective study","volume":"13","author":"Massud","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jctube.2025.100515_b0130","unstructured":"Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK541070\/."},{"issue":"2","key":"10.1016\/j.jctube.2025.100515_b0135","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jctube.2025.100515_b0140","unstructured":"WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]. Geneva: World Health Organization; 2022. Definitions. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588561\/."},{"key":"10.1016\/j.jctube.2025.100515_b0145","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/TCRM.S381800","article-title":"Incidence and predictors of adverse drug events among people receiving drug resistant tuberculosis treatment in uganda: 8-year retrospective cohort study","volume":"18","author":"Nasasira","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jctube.2025.100515_b0150","doi-asserted-by":"crossref","unstructured":"Buziashvili M, Davtyan H, Sereda Y, Denisiuk O, Gozalov O, Lomtadze N, et al. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018. Monaldi Arch Chest Dis. 2021;91(1).","DOI":"10.4081\/monaldi.2021.1649"},{"issue":"4","key":"10.1016\/j.jctube.2025.100515_b0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/picr.PICR_165_17","article-title":"Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot","volume":"9","author":"Piparva","year":"2018","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.jctube.2025.100515_b0160","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.12659\/MSM.904682","article-title":"Adverse events associated with treatment of multidrug-resistant tuberculosis in china: an ambispective cohort study","volume":"23","author":"Zhang","year":"2017","journal-title":"Med Sci Monit"},{"issue":"28","key":"10.1016\/j.jctube.2025.100515_b0165","doi-asserted-by":"crossref","first-page":"e7482","DOI":"10.1097\/MD.0000000000007482","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jctube.2025.100515_b0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study","volume":"34","author":"Dela","year":"2017","journal-title":"Lung India"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0970-258X.308234","article-title":"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India","volume":"33","author":"Rupani","year":"2020","journal-title":"Natl Med J India"},{"issue":"4","key":"10.1016\/j.jctube.2025.100515_b0180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1515\/jbcpp-2020-0447","article-title":"Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study","volume":"32","author":"Nilamsari","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.jctube.2025.100515_b0185","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.2147\/IDR.S369715","article-title":"High incidence of psychiatric disorders associated with cycloserine treatment of multidrug-resistant tuberculosis patients: a cohort study in Beijing China","volume":"15","author":"Pang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jctube.2025.100515_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.876955","article-title":"Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: a prospective cohort study from Pakistan","volume":"13","author":"Khan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jctube.2025.100515_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40360-020-00464-9","article-title":"Common causes and characteristics of adverse drug reactions in older adults: a retrospective study","volume":"21","author":"Woo","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.jctube.2025.100515_b0200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/11631760-000000000-00000","article-title":"Adverse drug reactions in older people: detection and prevention","volume":"29","author":"Petrovic","year":"2012","journal-title":"Drugs Aging"},{"issue":"11","key":"10.1016\/j.jctube.2025.100515_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027610","article-title":"Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru","volume":"6","author":"Chung-Delgado","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jctube.2025.100515_b0210","article-title":"Tuberculosis-associated anemia: a narrative review","volume":"14","author":"Dasaradhan","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jctube.2025.100515_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245458","article-title":"Anemia in tuberculosis cases: a biomarker of severity?","volume":"16","author":"de Mendon\u00e7a","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jctube.2025.100515_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071477","article-title":"Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art","volume":"9","author":"Minardi","year":"2021","journal-title":"Microorganisms"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:30:15Z","timestamp":1762623015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579425000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"alternative-id":["S2405579425000063"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100515","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100515"}}